K36 Therapeutics
k36tx.comLocations
Cambridge, MA, USA · Cambridge, MA, USA
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series B
founded in
2021
K36 Therapeutics is focused on developing breakthrough therapies for cancer patients with unmet medical needs, particularly targeting multiple myeloma. Their lead candidate, KTX-1001, is a first-in-class selective inhibitor of the histone methyltransferase MMSET, which is overexpressed in a subset of multiple myeloma patients. This innovative approach aims to provide a targeted therapy that addresses the underlying causes of cancer, positioning K36 Therapeutics as a leader in the epigenetic modulation of oncogenic pathways.
Something looks off?Open jobs at K36 Therapeutics
This company does not have jobs relevant to this job board at this time.
To view all their jobs, visit their website.